重组人脑利钠肽治疗冠心病急性心肌梗死后心力衰竭的疗效与安全性

Curative Effect and Security of Recombinant Human Brain Natriuretic Pep-tide in Treatment of Heart Failure after Coronary Heart Disease Acute My-ocardial Infarction

目的研究重组人脑利钠肽治疗冠心病急性心肌梗死后心力衰竭的疗效与安全性。方法整群选择2012年8月—2013年11月该院心内科收治的急性心梗后心力衰竭患者136例,随机法分为观察组(n=70)和对照组(n=66),对照组给予硝酸甘油治疗,观察组给予重组人脑利钠肽治疗,比较两组患者治疗效果及安全性。结果观察组总有效率81.4%与对照组63.6%比较差异有统计学意义(P<0.05)。观察组不良反应率10.0%与对照组15.2%比较差异无统计学意义(P>0.05)。结论重组人脑利钠肽通过扩张动静脉,降低心脏的前、后负荷,达到减轻患者呼吸困难及全身症状的作用,安全性高。

Objective To research the curative effect and security of recombinant human brain natriuretic peptide in treatment of heart failure after coronary heart disease acute myocardial infarction. Methods 136 cases of patients with heart failure after coronary heart disease acute myocardial infarction treated in the department of cardiology in our hospital from August 2012 to November 2013 were selected and randomly divided into the observation group（n=70）and the control group（n=66）, the control group were treated with glyceryl trinitrate, the observation group were treated with recombinant human brain natriuretic peptide, the treatment effect and security of the two groups were compared. Results The difference in the total effective rate between the observation group and the control group was statistically significant（81.4% vs 63.6%）（P0.05）, the difference in the adverse reaction rate between the observation group and the control group was not statistically significant（10.0% vs 15.2%）（P0.05）. Conclusion Recombinant human brain natriuretic peptide reduces the pre load and post load of heart by expanding the arteriovenous thus relieving the patient＇s dyspnea and constitutional symptom with high security.